RxDoctor Payments Data

Marie-Claire Buckley, MD

Plastic and Reconstructive Surgery · Minneapolis, MNNPI 1730116971

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,500 of the $8,493 with a category attached, or 88.3%. Solventum Corporation accounts for 76.5% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $6,731, more than ten times the $352 reported in 2019. Among plastic and reconstructive surgery clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,493in general payments, 2019–2025

Across 20 payments — averaging $424.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Solventum Corporation$7K
  • KCI USA, Inc.$1K
  • My01 Inc.$197
  • Kerecis Limited$164
  • Aroa Biosurgery Incorporated$139
  • Lifenet Health$109
  • plus $384 from 6 others

What the payments were for

  • Speaking & faculty fees$7,50088%
  • Food & beverage$99312%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,493 in reported general payments places this provider in the 90th percentile of 33 plastic and reconstructive surgery providers in Minnesota.

See all plastic and reconstructive surgery providers in Minnesota

Medicare billing

Part B allowed, 2024
$24,605
Medicare patients
60
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydromorphone Hcl11$221

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →